FY2030 EPS Estimates for OTCMKTS:MDNAF Reduced by Analyst

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities researchers at HC Wainwright dropped their FY2030 EPS estimates for Medicenna Therapeutics in a note issued to investors on Tuesday, February 17th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.23 per share for the year, down from their prior forecast of $0.25.

Medicenna Therapeutics (OTCMKTS:MDNAF) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Separately, Zacks Research upgraded Medicenna Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy”.

Medicenna Therapeutics Price Performance

Shares of Medicenna Therapeutics stock opened at $0.63 on Wednesday. Medicenna Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.43. The firm has a market cap of $52.55 million, a P/E ratio of -5.73 and a beta of 1.81.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.